DPM1 Activators
DPM1 activators are chemical compounds that enhance the function of DPM1, a key enzyme in the biosynthesis of dolichol-linked oligosaccharides, through direct or indirect interaction with the protein and the pathways it is involved in. Dolichol phosphate and mannose directly enhance the functional activity of DPM1. Dolichol phosphate serves as a carrier in the biosynthesis of glycoproteins, while mannose acts as a substrate for DPM1 in the mannose-rich glycosylation pathway, directly providing the necessary components for DPM1 to function effectively.
Other compounds, including Cerulenin, Fluvastatin, Mevalonic acid, Fumonisin B1, Simvastatin, Lovastatin, Pravastatin, Atorvastatin, and Rosuvastatin, indirectly enhance DPM1's activity by influencing pathways and processes related to DPM1 function. Cerulenin and Fumonisin B1 inhibit enzymes in the fattyacid synthesis and sphingolipid metabolism respectively, potentially increasing the availability of substrates for the glycosylation pathway in which DPM1 is involved. The statin compounds (Fluvastatin, Simvastatin, Lovastatin, Pravastatin, Atorvastatin, Rosuvastatin) inhibit HMG-CoA reductase, a key enzyme in the mevalonate pathway, leading to an increase in the availability of substrates for the glycosylation pathway. Mevalonic acid, a precursor in the biosynthesis of dolichol phosphate, provides necessary components for the function of DPM1. These compounds, by influencing related pathways or processes, enhance the functional activity of DPM1.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-Mannose | 3458-28-4 | sc-211180 sc-211180A | 100 g 250 g | $103.00 $161.00 | 1 | |
Mannose contributes to the mannose-rich glycosylation pathway, where it acts as a substrate for DPM1. Increased availability of mannose can enhance DPM1's functional activity by providing more substrate for the enzyme to act upon. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
Cerulenin inhibits fatty acid synthase, which indirectly could lead to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved. This can provide more substrate for DPM1 to act upon, thus enhancing its function. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway. This could lead to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved, enhancing its function. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
Fumonisin B1 inhibits ceramide synthase, potentially leading to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved, thereby enhancing its function. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway. This could lead to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved, enhancing its function. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway. This could lead to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved, enhancing its function. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $69.00 $162.00 $787.00 | 2 | |
Pravastatin inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway. This could lead to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved, enhancing its function. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway. This could lead to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved, enhancing its function. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the mevalonate pathway. This could lead to an increase in the availability of substrates for the glycosylation pathway where DPM1 is involved, enhancing its function. | ||||||